Wanbury Ltd Delivers Strong Q3 FY26 Performance with 21.7% Revenue Growth and 1,194.3% PAT Growth

Wanbury Ltd, a pharmaceutical company, has announced its financial results for the quarter and nine months ended 31st December 2025. The company reported a Y-o-Y growth of 21.7% in revenue from operations for Q3 FY26, driven by higher AP! volumes, improved capacity utilization at key manufacturing facilities and steady performance in the formulations business. The EBITDA for Q3 FY26 stood at Rs. 26.9 crore, registering a growth of 81.7%. The PAT for the quarter stood at Rs. 15.8 crore, registering a significant growth of 1,194.3%. For the nine months ended December 31, 2025, the revenue from operations stood at Rs. 485.7 crore, up from Rs. 427.5 crore in 9M FY25, reflecting a Y-o-Y growth of 13.6%. The EBITDA for 9M FY26 stood at Rs. 77.6 crore, a Y-o-Y growth of 60.6%. The PAT for 9M FY26 stood at Rs. 44.4 crore, registering a growth of 332.5%.